We further show that the level of BECN1 Y333 phosphorylation is a predictor of colorectal cancer patient outcome and that JAK2 inhibitor treatment combined with chemotherapy is more effective in inhibiting cancer cell growth. This evidence concerns the gene JAK2 and colorectal cancer.